Shanghai Fosun Pharmaceutical (Group)
Market Cap
CN¥61.9b
Last Updated
2019/10/20 14:35 UTC
Data Sources
Company Financials +
Executive Summary
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally.
Snowflake
Fundamentals
Established dividend payer and good value.
Similar Companies
Share Price & News
How has Shanghai Fosun Pharmaceutical (Group)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.08%
600196
0.5%
CN Pharmaceuticals
-1.3%
CN Market
1 Year Return
-11.3%
600196
25.7%
CN Pharmaceuticals
25.5%
CN Market
Shareholder returns
| 600196 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.08% | 0.5% | -1.3% |
| 30 Day | -9.5% | -0.3% | -3.0% |
| 90 Day | -4.3% | 9.1% | 2.6% |
| 1 Year | -10.2%-11.3% | 27.2%25.7% | 27.7%25.5% |
| 3 Year | 12.9%9.0% | -7.0%-9.9% | -11.1%-14.6% |
| 5 Year | 42.9%34.3% | 32.9%26.6% | 38.2%30.0% |
Price Volatility Vs. Market
How volatile is Shanghai Fosun Pharmaceutical (Group)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Shanghai Fosun Pharmaceutical (Group) undervalued compared to its fair value and its price relative to the market?
35.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: 600196 (CN¥25.34) is trading below our estimate of fair value (CN¥39.38)
Significantly Undervalued: 600196 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 600196 is good value based on its PE Ratio (24.3x) compared to the Pharmaceuticals industry average (29.8x).
PE vs Market: 600196 is good value based on its PE Ratio (24.3x) compared to the CN market (31.5x).
Price to Earnings Growth Ratio
Low PEG Ratio: 600196 is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: 600196 is good value based on its PB Ratio (2.3x) compared to the CN Pharmaceuticals industry average (2.5x).
Next Steps
Future Growth
How is Shanghai Fosun Pharmaceutical (Group) forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
12.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600196's forecast earnings growth (12.8% per year) is above the savings rate (2.7%).
Earnings vs Market: 600196's earnings (12.8% per year) are forecast to grow slower than the CN market (18.4% per year).
High Growth Earnings: 600196's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600196's revenue (16.7% per year) is forecast to grow faster than the CN market (15.2% per year).
High Growth Revenue: 600196's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Information is not available.
Next Steps
Past Performance
How has Shanghai Fosun Pharmaceutical (Group) performed over the past 5 years?
6.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 600196's earnings have grown by 6.3% per year over the past 5 years.
Accelerating Growth: 600196's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600196 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.3%).
Return on Equity
High ROE: 600196's Return on Equity (9%) is considered low.
Return on Assets
ROA vs Industry: 600196's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 600196's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Shanghai Fosun Pharmaceutical (Group)'s financial position?
Financial Position Analysis
Short Term Liabilities: 600196's short term assets (CN¥18.4B) exceeds its short term liabilities (CN¥17.8B)
Long Term Liabilities: 600196's short term assets (18.4B) do not cover its long term liabilities (21.3B)
Debt to Equity History and Analysis
Debt Level: 600196's debt to equity ratio (68.9%) is considered high
Reducing Debt: 600196's debt to equity ratio has increased from 40.4% to 68.9% over the past 5 years.
Debt Coverage: 600196's debt is not well covered by operating cash flow (13.1%).
Interest Coverage: 600196 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Information is not available.
Information is not available.
Next Steps
Dividend
What is Shanghai Fosun Pharmaceutical (Group)'s current dividend yield, its reliability and sustainability?
1.26%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 600196's dividend (1.26%) is higher than the bottom 25% of dividend payers in the CN market (0.46%).
High Dividend: 600196's dividend (1.26%) is low compared to the top 25% of dividend payers in the CN market (1.93%).
Stable Dividend: 600196's dividends per share have been stable in the past 10 years.
Growing Dividend: 600196's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (30.7%), 600196's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 600196's dividends in 3 years are forecast to be well covered by earnings (28.5% payout ratio).
Next Steps
Management
What is the CEO of Shanghai Fosun Pharmaceutical (Group)'s salary, the management and board of directors tenure and is there insider trading?
4.3yrs
Average management tenure
CEO
Yifang Wu (50yo)
3.3yrs
Tenure
CN¥8,333,000
Compensation
Mr. Yifang Wu has been the Chief Executive Officer and President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since June 7, 2016. Mr. Wu serves as the President of Wanbang Biopharmaceuticals Co., Ltd ...
CEO Compensation Analysis
Information is not available.
Compensation vs Earnings: Yifang's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Management Age and Tenure
4.3yrs
Average Tenure
49.5yo
Average Age
Experienced Management: 600196's management team is considered experienced (4.3 years average tenure).
Board Age and Tenure
3.2yrs
Average Tenure
50yo
Average Age
Experienced Board: 600196's board of directors are considered experienced (3.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 140,000 |
| Max Price | CN¥22.98 |
| Entity | Company |
| Shares | 40,000 |
| Max Price | CN¥22.17 |
| Entity | Company |
| Shares | 640,000 |
| Max Price | CN¥22.33 |
| Entity | Company |
| Shares | 79,800 |
| Max Price | CN¥24.10 |
| Entity | Company |
| Shares | 620,000 |
| Max Price | CN¥23.54 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 20,000 |
| Max Price | CN¥26.30 |
Ownership Breakdown
Management Team
Fang Yao (50yo)
Executive Director
- Tenure: 9.3yrs
- Compensation: CN¥9.90m
Qiyu Chen (47yo)
Chairman
- Tenure: 0yrs
- Compensation: CN¥14.25m
Kexin Wang (55yo)
Senior Vice President
- Tenure: 0yrs
Xiaohui Guan (48yo)
Senior VP & CFO
- Tenure: 4.3yrs
Yifang Wu (50yo)
President
- Tenure: 3.3yrs
- Compensation: CN¥8.33m
Cheng Wang (56yo)
Senior Vice President
- Tenure: 0yrs
Biao Zhou (49yo)
Senior Vice President
- Tenure: 5.7yrs
Yuqing Chen (44yo)
Senior Vice President
- Tenure: 0yrs
Donghua Wang (50yo)
VP and GM of Public Affairs Department & Administration Department
- Tenure: 0yrs
Xiaoxian Dong (38yo)
Senior VP
- Tenure: 0yrs
Board Members
Kelvin Wong (59yo)
Independent Non-Executive Director
- Tenure: 4.3yrs
- Compensation: CN¥300.00k
Fang Yao (50yo)
Executive Director
- Tenure: 9.3yrs
- Compensation: CN¥9.90m
Guliang Tang (56yo)
Independent Non-Executive Director
- Tenure: 0.3yrs
Qiyu Chen (47yo)
Chairman
- Tenure: 0yrs
- Compensation: CN¥14.25m
Xiaoliang Xu (46yo)
Non Executive Director
- Tenure: 0.3yrs
Yifang Wu (50yo)
President
- Tenure: 3.3yrs
- Compensation: CN¥8.33m
Xian Jiang (64yo)
Independent Non-Executive Director
- Tenure: 4.3yrs
- Compensation: CN¥300.00k
Robin Wang (40yo)
Non-Executive Director
- Tenure: 3.3yrs
Haining Mu (46yo)
Non-Executive Director
- Tenure: 1.3yrs
Qian Ren (50yo)
Chairman of Supervisory Committee
- Tenure: 1.8yrs
Company Information
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Ticker: 600196
- Exchange: SHSE
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥61.923b
- Shares outstanding: 2.56b
- Website: https://www.fosunpharma.com
Number of Employees
Location
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Building A
- No. 1289 Yishan Road
- Shanghai
- 200233
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 600196 | SHSE (Shanghai Stock Exchange) | Yes | Domestic Shares | CN | CNY | Aug 1998 |
| 600196 | XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect) | Yes | Domestic Shares | CN | CNY | Aug 1998 |
| 2196 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Foreign Shares-Foreign Listed | HK | HKD | Oct 2012 | |
| SFOS.F | OTCPK (Pink Sheets LLC) | Foreign Shares-Foreign Listed | US | USD | Oct 2012 | |
| 08HH | BST (Boerse-Stuttgart) | Foreign Shares-Foreign Listed | DE | EUR | Oct 2012 | |
| 2196 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Foreign Shares-Foreign Listed | HK | HKD | Oct 2012 | |
| 2196 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Foreign Shares-Foreign Listed | HK | HKD | Oct 2012 |
Biography
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in fi ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/20 14:35 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.